Clinical Trials
RINGSIDE AL102 Phase 2/3 In 2023, Ayala Pharmaceuticals initiated recruitment for the Phase 3 part of the RINGSIDE trial of AL102 for the treatment of progressing desmoid tumors. This trial follows the positive results of the Phase 2 part of the trial. AL102 is a gamma secretase inhibitor (GSI) administered orally and once daily. Phase 3 is Placebo-controlled and includes relapsed/refractory (tumor recurred or grew after treatment/did not respond to treatment) or treatment-naïve patients (patients who have not had any treatment) with tumor growth in the last 12 months. The trial is enrolling patients who are 12 years old and older and is currently enrolling in the US, Australia, Spain, Israel and other countries. Follow posted updates on ClinicalTrials.gov website for additional locations as they open up. Recursion Phase 2 TUPELO Trial Recursion has initiated the TUPELO Trial, a Phase 2 trial of REC-4881, for the potential treatment of Familial Adenomatous Polyposis (FAP). The trial will include patients who have previously been diagnosed with classic Familial Adenomatous Polyposis (FAP) and have undergone colectomy or subtotal colectomy. FAP patients with desmoid tumors may qualify.
See other ongoing trials which include desmoid tumors at ClinicalTrials.gov.
10
Made with FlippingBook Online newsletter maker